Roche R&D Operations Controlled By 'Go … Wait … Or Gate'
Executive Summary
Extensive pipeline comes with a corresponding challenge: how to manage it efficiently; COO O'Day explains how Roche built decision-making system centered on data analytics.
You may also be interested in...
Roche's Oncology Strategy: The Long Game Comes Into Focus
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.